A partnership will make available a new treatment for cats infected with leukemia and immunodeficiency viruses.
Through a recent partnership, T-Cyte Therapeutics Inc. will manufacture Lymphocyte T-Cell Immunomodulator (LTCI) while Imulan BioTherapeutics LLC will focus on technical services, clinical trials and product distribution.
LTCI is conditionally approved as a treatment aid for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) infections.
“We are delighted to partner with T-Cyte and make available the only approved treatment in the United States for cats infected with leukemia and immunodeficiency viruses,” said Craig Woods, DVM, chief executive officer of Imulan. “This technology represents an important advancement in immune based treatment strategies for animal health diseases.”
Imulan is based in Scottsdale, Ariz. T-Cyte, a subsidiary of S-Cell Biosciences, is based in San Diego.